Merck & Co.
AWARDS
NEWS
‘Our track record in R&D was not great for a few years...’
Late on Friday, Merck announced that it had pulled its application for Keytruda in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous NSCLC from the EMA.
Merck released its third-quarter financial results today, and along with it a hint--just a hint--that there might be some M&A deals in the future.
Incyte has been at the forefront of the IDO race with its candidate epacadostat.
The particular areas where sales jobs will be thinned are primary care, disease-focused endocrinology and hospital chronic care.
Analysts with SunTrust Robinson Humphrey recently published a research report that looked at a number of large-cap pharma companies.
JOBS
IN THE PRESS